Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national in-pharmacy marketing campaign to put its products in the shelves across Maccabi's pharmacy network in Israel.

Maccabi is Israel's second-largest health maintenance organization, serving over 2.8 million insured members nationwide. The initial sales and marketing campaign demonstrates that the Company's agreement with Maccabi has transitioned to active commercial execution, enabling broad patient access to TempraMed's temperature-protection products directly through Maccabi pharmacies.

The national campaign is designed to support sales, drive awareness, education, and adoption among patients managing temperature-sensitive medications such as insulin and epinephrine auto-injectors, reinforcing proper medication handling and real-world protection. TempraMed's products are now available at the point of care for one of the largest insured populations in the country.

"This is an important operational and commercialization milestone for TempraMed as this is the first time our products will be sold to customers in store and online," said Ron Nagar, CEO of TempraMed. "Shipping product and launching a nationwide campaign across the Maccabi brick and mortar pharmacy network demonstrates our ability to execute at scale within a large healthcare system. It reflects growing demand for practical solutions that protect medication efficacy in everyday life and supports our broader strategy of expanding through institutional healthcare channels."

The Maccabi rollout builds on TempraMed's growing global footprint, which includes sales through major retail, pharmacy, and healthcare channels in North America and internationally. Management views the national pharmacy campaign as an important commercialization step for driving recurring demand, strengthening brand presence within healthcare systems, and supporting future expansion across additional HMOs, payors, and institutional partners.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. Is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.

Cautionary Statements

This press release contains "forward-looking statements or information". Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated benefits and scope of the Maccabi pharmacy rollout; the Company's ability to drive awareness, education, and adoption of its products among patients managing temperature-sensitive medications; expectations regarding recurring demand from the national pharmacy campaign; the Company's ability to expand through institutional healthcare channels, including additional HMOs, payors, and institutional partners; the strengthening of the Company's brand presence within healthcare systems; the Company's broader commercialization strategy and global expansion plans; and the Company's ability to execute at scale within large healthcare systems.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to maintain and expand its commercial relationship with Maccabi Healthcare Services; risks related to the success and scalability of the national in-pharmacy campaign; the Company's ability to generate recurring revenue and sustained demand through the Maccabi pharmacy network; the Company's ability to secure additional partnerships with HMOs, payors, and institutional partners in Israel and internationally; risks related to market acceptance and adoption of the Company's temperature-protection products by patients and healthcare providers; the Company's ability to manage supply chain, logistics, and distribution across a national pharmacy network; regulatory and compliance risks in Israel and other international markets; the adequacy of the Company's cash flow and earnings to support ongoing commercialization efforts; the availability of future financing and/or credit; competition from existing or new entrants in the temperature-controlled medication storage market; general economic, market, or business conditions in Israel and globally; currency exchange rate fluctuations; loss of key employees and consultants; and other risks described in the Company's public filings.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282915